Nuwellis, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Nuwellis, Inc. on June 22, 2021. The filing discloses the appointment of George Montague as Chief Financial Officer and Treasurer, effective June 28, 2021. The company is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol NUWE.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and appointment details.
Material Changes
The primary material change reported is the addition of George Montague to the executive team. Mr. Montague brings prior experience as CFO and COO of Smiths Medical and in leadership roles at Medtronic plc. No changes to financial results or operational status are reported in this document.
Compensation, Outlook, and Risks
Compensation Arrangements:
- Base Salary: $325,000 annually.
- Bonus: Up to 45% of base salary, pro-rated for 2021.
- Equity: Option to purchase 62,535 shares under the 2021 Inducement Plan. Vesting includes 25% on the one-year anniversary and the remainder in 36 equal monthly increments.
- Severance: In the event of termination without Cause, the company will provide one year of base salary and COBRA premium reimbursement.
- Change in Control: Unvested equity awards will fully vest immediately prior to a Change in Control. Additional severance applies if termination occurs within one year of a Change in Control without Cause or for Good Reason.
Risks and Contingencies:
The filing notes that Mr. Montague is subject to non-solicitation and non-competition requirements. The employment is "at-will," allowing termination by either party at any time. The filing does not provide specific guidance or outlook on future financial performance.
Key Facts for Investor Verification
- Verify the effective start date of George Montague as CFO (June 28, 2021).
- Review the specific vesting schedule for the 62,535 stock options granted under the 2021 Inducement Plan.
- Confirm the terms of the Change in Control Agreement regarding accelerated vesting and severance.
- Note that this filing contains no financial results; refer to the most recent 10-K or 10-Q for financial metrics.